<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39230521</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1935-3227</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Journal of addiction medicine</Title><ISOAbbreviation>J Addict Med</ISOAbbreviation></Journal><ArticleTitle>Response to "Two Clinical Insights on Methamphetamine Withdrawal at a Safety-Net Hospital".</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/ADM.0000000000001364</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilens</LastName><ForeName>Timothy E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>twilens@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Ronan L H</ForeName><Initials>RLH</Initials></Author><Author ValidYN="Y"><LastName>Beltrame</LastName><ForeName>Lia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>O'Connell</LastName><ForeName>James</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Addict Med</MedlineTA><NlmUniqueID>101306759</NlmUniqueID><ISSNLinking>1932-0620</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflicts of Interest: Dr. Timothy Wilens has received research funding from the National Institutes of Health through the HEAL Initiative under award number 1UG3DA050252-01 and 4UH3DA050252-02 and the Food and Drug Administration. Dr. Wilens works as a clinical consultant f or the Gavin Foundation, Bay Cove Human Services, and US Minor and Major League for Baseball. He has licensing and/or intellectual property agreements with Ironshore and White Rhino/3D Therapy LLC. Dr. James O’Connell works as a medical director for the Gavin Foundation and Bay Cove Human Services. At the time of protocol development and implementation, Adam Taylor and Lia Beltrame were employees of Bay Cove Human Services. Ronan Wilson does not have any conflicts of interest to report and is an employee of Massachusetts General Hospital.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>4</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>4</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>4</Day><Hour>10</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39230521</ArticleId><ArticleId IdType="doi">10.1097/ADM.0000000000001364</ArticleId><ArticleId IdType="pii">01271255-990000000-00370</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beckett AH, Salmon JA, Mitchard M. The relation between blood levels and urinary excretion of amphetamine under controlled acidic and under fluctuating urinary pH values using [14C] amphetamine. J Pharm Pharmacol. 1969;21(4):251–258.</Citation></Reference><Reference><Citation>Huang W, Czuba LC, Isoherranen N. Mechanistic PBPK modeling of urine pH effect on renal and systemic disposition of methamphetamine and amphetamine. J Pharmacol Exp Ther. 2020;373(3):488–501.</Citation></Reference><Reference><Citation>Cook CE, Jeffcoat AR, Sadler BM, et al. Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. Drug Metab Dispos. 1992;20(6):856–862.</Citation></Reference><Reference><Citation>Kim I, Oyler JM, Moolchan ET, et al. Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. Ther Drug Monit. 2004;26(6):664–672.</Citation></Reference><Reference><Citation>Adderall [package insert]. Horsham, PA: Teva Select Brands. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/011522s043lbl.pdf. Published January 2017.</Citation></Reference><Reference><Citation>Desoxyn [package insert]. Lebanon, NJ: Recordati Rare Diseases, Inc. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/005378s034lbl.pdf. Published February 2015.</Citation></Reference><Reference><Citation>Ascor [package insert]. Santa Ana, CA: McGuff Pharmaceuticals, Inc. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209112s000lbl.pdf. Published July 2022.</Citation></Reference><Reference><Citation>Huang YN, Yang LY, Wang JY, et al. L-ascorbate protects against methamphetamine-induced neurotoxicity of cortical cells via inhibiting oxidative stress, autophagy, and apoptosis. Mol Neurobiol. 2017;54(1):125–136.</Citation></Reference><Reference><Citation>Huang YN, Wang JY, Lee CT, et al. L-ascorbate attenuates methamphetamine neurotoxicity through enhancing the induction of endogenous heme oxygenase-1. Toxicol Appl Pharmacol. 2012;265(2):241–252.</Citation></Reference><Reference><Citation>Wagner GC, Jarvis MF, Carelli RM. Ascorbic acid reduces the dopamine depletion induced by MPTP. Neuropharmacology. 1985;24(12):1261–1262.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>